
Feds launch crackdown on kratom byproduct
Why it matters: The compound, 7-hydroxymitragynine, is commonly sold online and in smoke shops and has been found in dangerous concentrations in tablets, gummies and drink mixes.
Driving the news: FDA and Drug Enforcement Administration officials said Tuesday they are taking steps to schedule the compound as a controlled substance and released a report on its risks to educate the medical community, schools and parents.
The FDA has also issued warning letters to seven companies for illegal marketing products containing 7-OH. The products advertise the compound as an added ingredient, or being included at enhanced levels.
Distributors claim products with the substance act as "unapproved new drugs with unproven claims such as relieving pain and managing anxiety," the agency said.
HHS Secretary Robert F. Kennedy Jr. referenced his own history with heroin addiction at a Tuesday event promoting the crackdown, during which he described the importance of cracking down on the easily available synthetic opioid.
"I became an addict because [heroin] was so available, but I had to go to the South Bronx or the Lower East Side. But now you can go to any gas station," Kennedy said.
"They're putting them around schools, putting them in our poorest neighborhoods and now they are putting them in every gas station," he continued. "They're marketing them to children, they're gummy bears, they're bright colors, they're candy flavored. This is really a sinister, sinister industry."
Officials said they are not targeting the herbal supplement kratom but the byproduct.
Research has shown 7-OH can be 13 times more potent than morphine, FDA Commissioner Marty Makary said.
"7-OH is not just 'like' an opioid ... it is an opioid," Makary said. "And yet it is sold in vape stores, in smoke shops, in convenience stores, in gas stations that are popping up around the United States. And no one knows what it is."
He declined to weigh in on the safety of kratom products, which have intoxicating effects and have been the target of new and proposed restrictions in Colorado and Louisiana.
"Lets not let another wave of the opioid epidemic catch us blind-sided again," Makary said.
The move was cheered by some kratom proponents who say the agency's action differentiates what's illegal from legitimate products.
"For too long, the conversation around kratom has been polluted by bad actors and misinformation," said Paula Brown, director of Natural Health & Food Products Research at the British Columbia Institute of Technology.
"FDA's data now supports what pharmacognosists have known for years: kratom is not a narcotic, and 7-OH is not a natural constituent of the plant. Differentiating them is both scientifically necessary and ethically urgent."
The other side: "Over half a billion doses of 7-OH have been used without a single confirmed death. That's not a threat to public safety—that's a success story," said Jeff Smith, National Policy Director of the Holistic Alternative Recovery Trust (HART). "This compound deserves to be regulated like any responsible product."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
You're Ruining Your Gains If You Skip These 8 Recovery Foods
You're Ruining Your Gains If You Skip These 8 Recovery Foods originally appeared on Men's Fitness. Men's Fitness aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. After an intense workout, the body needs to repair damaged muscle tissue. Pick the right food and you can jump-start that recovery process without ruining the gains you made in the gym. Amino acids—the building blocks of protein—are essential to bolstering recovery. And to ensure you get adequate amino acids, you need to eat protein. Your body also needs glycogen, found in carb-rich foods, since stores gets depleted during training. Eating a combo of protein and carbs is key to workout recovery, and foods that are good sources of both should become staples in your diet. Add these eight healthy eats to your diet to maximize recovery after a workout. Best Post-Workout Recovery Foods Lean Meat Although our bodies produce non-essential amino acids, we also need essential amino acids, ones that are not made in the body and must be consumed from our diets. One of the best sources of essential amino acids is lean meat such as chicken, turkey, and ground beef. According to the FDA, a 'lean' meat contains less than 10 grams of fat, 4.5 grams or less of saturated fat, and less than 95 milligrams of cholesterol per 100 grams. Choose meats that are at least 90 percent lean to ensure you're not getting too much saturated fat and cholesterol. Quinoa One cup of cooked quinoa contains about 8 grams of protein and 40 grams of carbohydrates, making it a nutrient-packed post-workout dish. Unlike other grains, quinoa is a complete protein since it contains all nine essential amino acids, which results in better muscle recovery and more energy. Plain Greek Yogurt Greek yogurt has 15 to 20 grams of protein per 6 ounces compared to 9 grams of protein in an identical serving of regular yogurt. The protein in Greek yogurt is predominantly casein, which digests slower than whey and boasts a full essential amino acid profile. Opt for plain Greek yogurt since it has substantially less sugar than flavored Greek yogurt. To really capitalize on the benefits of casein, eat it before bedtime for extended amino acid digestion. Smoothies Smoothies make a great post-workout recovery drink because of the instant absorption of a custom assortment of nutrients. Just be mindful of how much sugar you add—piling on the fruit can quickly turn a post-workout "nutrition shake" into a secret sugar bomb. Bananas Nature designed the humble banana to be a post-workout recovery machine. One serving includes about 27 grams of carbohydrates, an essential energy resource to ignite your body's muscle repair systems. Additionally, a potassium-packed banana replenishes the depleted electrolyte stores in your muscles, reducing soreness and speeding up the recovery process. The best part is that bananas are naturally sweet, which means it's an ideal addition to a post-workout protein shake or smoothie without adding any refined sugar. Low-fat Chocolate Milk The perfect recovery ratio of carbohydrates to protein is 4:1, according to a growing collection of studies. Chocolate milk matches this ratio better than any sugary sports drink, turning the lunch box staple into a powerful recovery option. A study from Applied Physiology, Nutrition, and Metabolism also found exercisers are able to retain more than twice the amount of fluid in chocolate milk than in a sports drink after a workout, meaning the body is able to absorb more protein with less volume. Avocados Bananas get all the attention when it comes to potassium, but avocados actually have an average of 35 percent more per serving. The fruit is also full of monosaturated fats, which have been linked to reducing cholesterol levels. With an additional 3 grams of protein, vital for muscle growth, the avocado is a filling addition to a post-workout meal. Sweet Potatoes Another potassium powerhouse, the sweet potato contains 448 milligrams in one serving. Because of its orange hue it also comes packed with carotenoids—compounds that aid cell repair, which is vital during the recovery process after a workout. The starchy carbs from sweet potatoes also help restock energy stores, while the fiber will keep you full and encourage you not to spring for something less healthy later in the Ruining Your Gains If You Skip These 8 Recovery Foods first appeared on Men's Fitness on Aug 1, 2025 This story was originally reported by Men's Fitness on Aug 1, 2025, where it first appeared. Solve the daily Crossword


NBC News
6 hours ago
- NBC News
U.S. farm agency allows six more states to bar some items from food aid
WASHINGTON - The U.S. Department of Agriculture on Monday allowed six additional states to bar participants in the Supplemental Nutrition Assistance Program from using their benefits to buy certain processed foods, such as sodas and candy. The SNAP waivers for West Virginia, Florida, Colorado, Louisiana, Oklahoma and Texas amend the statutory definition of food for purchase and put an end to the subsidization of popular types of junk food beginning in 2026. The administration of President Donald Trump has encouraged all states to take such measures as part of its 'Make America Healthy Again' initiative, named for the social movement led by Health Secretary Robert F. Kennedy Jr. The USDA had so far signed waivers to allow six states — Arkansas, Idaho, Utah, Iowa, Indiana and Nebraska — to place similar purchasing restrictions on SNAP recipients. 'I hope to see all 50 states join this bold commonsense approach. For too long, the root causes of our chronic disease epidemic have been addressed with lip service only,' said the U.S. Food and Drug Commissioner Marty Makary. Agriculture Secretary Brooke Rollins announced the additional waivers at an event at the USDA headquarters in Washington. 'These state waivers promote healthier options for families in need,' said Secretary Rollins. More than 42 million people receive SNAP benefits, sometimes called food stamps, as part of the nation's largest anti-hunger program. The massive tax cut and spending bill signed by President Trump in July makes significant changes to the SNAP program, including expanding work requirements and shifting more spending for the program to states.
Yahoo
7 hours ago
- Yahoo
Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI3032
SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announced that the U.S. Food and Drug Administration (FDA) has approved the investigational new drug (IND) application to initiate a Phase 1 clinical trial of IBI3032, the company's novel oral GLP-1R agonist. IBI3032 is an orally administered small-molecule GLP-1 receptor agonist with bias for cAMP signaling pathway, discovered and developed by Innovent Biologics with proprietary rights. Preclinical data demonstrate its superior pharmacokinetic (PK) and physicochemical properties compared to peer compounds. In animal models, IBI3032 achieved 5 to 10 times higher oral exposure at equivalent doses, with improved efficacy and good tolerability in both GLP-1R KI DIO mice and obese monkey models, achieving comparable therapeutic effects at lower doses. The Phase 1 clinical trials of IBI3032 are planned to be conducted concurrently in China and the U.S. Dosing in healthy volunteers and overweight or obese participants is expected to begin in the second half of 2025. Innovent is building up its CVM pipeline with mazdutide as the cornerstone, and the initiation of the IBI3032 clinical study marks a significant step in the evolution of its CVM pipeline portfolio with global potential. Dr. Lei Qian, Chief R&D Officer for General Biomedicines Pipeline at Innovent Biologics, said, "GLP-1 has emerged as a blockbuster target over the past decade. Its oral form, with its convenience, flexibility, and unique advantage in combination treatment strategies, holds promise as a differentiated complement to GLP-1R-targeting biologicals. Beyond traditional applications in diabetes and weight management, oral GLP-1 possess potential in treating related diseases such as hypertension and OSA (obstructive sleep apnea). IBI3032 has demonstrated its promising efficacy profiles in animal models, where IBI3032 exhibited a longer elimination half-life and higher drug exposure levels than its competitors at the same dose. We are excited to advance this candidate into clinical development. This IND approval reflects Innovent's strong R&D capabilities and, most importantly, our commitment to global innovation. We hope that in the near future, IBI3032 can offer more effective and convenient treatment options to benefit patients around the world. " About IBI3032 IBI3032 is a novel oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1RA). By efficiently and selectively targeting GLP-1R, it activates downstream signal transduction, thereby delaying gastric emptying, inhibiting appetite, and promoting insulin secretion, and ultimately supporting the treatment of insulin-related metabolic diseases such as obesity and T2DB. Discovered through a structure-based drug design (SBDD) strategy combined with systematic physicochemical property optimization, IBI3032 has shown better PK and physicochemical properties compared to similar compounds. The IND application of IBI3032 was accepted by China's National Medical Products Administration (NMPA) and approved by the U.S. Food and Drug Administration (FDA). A multi-regional Phase 1 clinical study of IBI3032 is planned for initiation in the second half of 2025. About Innovent Biologics Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 16 products in the market. It has 2 new drug applications under regulatory review, 4 assets in Phase III or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit or follow Innovent on Facebook and LinkedIn. Statement: (1)Innovent does not recommend the use of any unapproved drug (s)/indication (s). (2)Ramucirumab (Cyramza),Selpercatinib (Retsevmo) and Jaypirca (pirtobrutinib) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics, Inc. ("Innovent" or "Company"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. View original content: SOURCE Innovent Biologics Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data